EGR1 and acute myeloid leukemia: In the JUN-dataset cohort, AML patients with high BATF expression and low EGR1 expression had the poorest outcomes (3-year OS: 26.92% vs. 44.90% and 64.71%, P = 0.02) (Figure 2A).